

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.(original): A stent for in vivo placement, said stent comprising being formed in a substantially tubular shape and expandable in the outward radial direction of the substantially tubular shape, containing a material nondegradable in vivo, and a poly (lactide-co-glycolide) on at least a portion of the surface thereof.

2.(original): The stent according to claim 1, wherein the poly (lactide-co-glycolide) is on either the outer surface or the inner surface of the stent.

3.(original): The stent according to claim 1, wherein the poly (lactide-co-glycolide) is over substantially the entire surface including the outer surface, the inner surface, and the side surfaces of the stent.

4.(currently amended): The stent according to ~~any one of~~ ~~claims~~ claim 1 ~~to 3~~, wherein the weight-average molecular weight of the poly (lactide-co-glycolide) is 5,000 to 130,000.

5.(currently amended): The stent according to ~~any one of~~ ~~claims~~ claim 1 ~~to 4~~, wherein the molar ratios of lactic acid and

glycolic acid which constitute the poly (lactide-co-glycolide)

are 50 mol% to 85 mol% and 15 mol% to 50 mol%, respectively.

6.(currently amended): The stent according to ~~any one of~~
~~claims claim 1 to 5~~, wherein the weight of the poly (lactide-co-
glycolide) being on the stent is 3 $\mu\text{g}/\text{mm}$ to 80 $\mu\text{g}/\text{mm}$ per unit
length in the axial direction of the stent.

7.(original): The stent according to claim 6, wherein the
weight of the poly (lactide-co-glycolide) being on the stent is 7
 $\mu\text{g}/\text{mm}$ to 65 $\mu\text{g}/\text{mm}$ per unit length in the axial direction of the
stent.

8.(original): A stent for in vivo placement comprising being
formed in a substantially tubular shape and expandable in the
outward radial direction of the substantially tubular shape,
containing a material nondegradable in vivo, and a poly (lactide-
co-glycolide) and an immunosuppressive agent on at least a
portion of the surface thereof.

9.(original): The stent according to claim 8, wherein the poly
(lactide-co-glycolide) and the immunosuppressive agent are on
either the outer surface or the inner surface of the stent.

10.(Original): The stent according to claim 8, wherein the
stent has the poly (lactide-co-glycolide) and the

immunosuppressive agent are over substantially the entire surface including the outer surface, the inner surface, and the side surfaces of the stent.

11.(currently amended): The stent according to ~~any one of~~ ~~claims~~ claim 8 ~~to 10~~, wherein the weight-average molecular weight of the poly (lactide-co-glycolide) is 5,000 to 130,000.

12.(currently amended): The stent according to ~~any one of~~ ~~claims~~ claim 8 ~~to 11~~, wherein the molar ratios of lactic acid and glycolic acid which constitute the poly (lactide-co-glycolide) are 50 mol% to 85 mol% and 15 mol% to 50 mol%, respectively.

13.(currently amended): The stent according to ~~any one of~~ ~~claims~~ claim 8 ~~to 12~~, wherein the immunosuppressive agent is tacrolimus (FK-506), cyclosporine, sirolimus (rapamycin), azathioprine, mycophenolate mofetil, or an analogue thereof.

14.(original): The stent according to claim 13, wherein the immunosuppressive agent is tacrolimus (FK-506).

15.(currently amended): The stent according to ~~any one of~~ ~~claims~~ claim 8 ~~to 14~~, wherein the total weight of the poly (lactide-co-glycolide) and the immunosuppressive agent contained in the stent is 3 µg/mm to 80 µg/mm per unit length in the axial direction of the stent.

16.(original): The stent according to claim 15, wherein the total weight of the poly (lactide-co-glycolide) and the immunosuppressive agent being on the stent is 7 $\mu\text{g}/\text{mm}$ to 65 $\mu\text{g}/\text{mm}$ per unit length in the axial direction of the stent.

17.(currently amended): The stent according to ~~any one of~~ ~~claims~~ claim 8 ~~to 16~~, wherein the weight ratios of the poly (lactide-co-glycolide) and the immunosuppressive agent are 30% by weight to 80% by weight and 20% by weight to 70% by weight, respectively.

18.(original): The stent according to claim 17, wherein the weight ratios of the poly (lactide-co-glycolide) and the immunosuppressive agent are 40% by weight to 70% by weight and 30% by weight to 60% by weight, respectively.

19.(currently amended): The stent according to ~~any one of~~ ~~claims~~ claim 8 ~~to 18~~, comprising an inner layer provided on a the surface of the stent, said inner layer containing the poly (lactide-co-glycolide) and the immunosuppressive agent, and an outer layer provided on the outer surface of the inner layer, said outer layer containing only the poly (lactide-co-glycolide).